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Abstract
Advance diagnostic and treatment modalities have improved outcomes for renal cell carcinoma (RCC) patients, but the prognosis for those with 
metastatic disease (mRCC) remains poor. As given metastatic distribution is critical in guiding treatment decisions for mRCC patients, we eval-
uated evolving metastatic patterns to assess if  our current practice standards effectively address patient needs. A systematic literature review was 
performed to identify all publicly available prospective clinical trials in metastatic renal cell carcinoma (mRCC) from 1990 to 2018. A total of 
16,899 mRCC patients from 127 qualified phase I–III clinical trials with metastatic site documentations were included for analysis for incidence 
of metastases to lung, liver, bone, and lymph nodes (LNs) over time. Studies were categorized into three treatment eras based on the timing of 
regulatory approval: Cytokine Era (1990-2004), vascular endothelial growth factor/tyrosine kinase inhibitor (TKI) Era (2005-2016), and immune 
checkpoint inhibitor/TKI Era (ICI-TKI, 2017-2018) and also classified as first-line only (FLO) or second-line and beyond (SLB). Overall, an 
increase in the incidence of bone and LNs metastases in FLO and SLB, and lung metastases in FLO, was seen over the three treatment eras. 
Generally, the burden of disease is higher in SLB when compared with FLO. Importantly, in the ICI-TKI era, the incidences of bone metastasis 
are 28% in FLO and 29% in SLB settings. The disease burden in patients with mRCC has increased steadily over the past three decades. Given 
the unexpectedly high rate of bone metastasis, routine dedicated bone imaging should be considered in all patients with mRCC.
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Kidney cancer is the eighth most common cancer in the 
United States, with an estimated 76,080 new cases in 
2021 (1). Approximately 35% of renal cell carcinoma (RCC) 
eventually becomes metastatic (mRCC), with the most com-
mon sites being lung, liver, bone, and lymph nodes (LNs) 
(1–3). As diagnostic imaging and systemic treatments for 
mRCC improve the detection of metastatic sites and biology 
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of the disease, also evolve. These can impact the selection, 
timing, and sequence of the present and future therapies. 
Diagnostically, computed tomography (CT) has long been 
the modality of choice, with much improvement in its res-
olution and reproducibility over the last three decades  (4). 
Increasing utilization of CT, magnetic resonance imag-
ing (MRI), and positron emission tomography (PET)-CT 
scans have led to earlier detection and a higher incidence 
of RCC (5). The Response Evaluation Criteria in Solid 
Tumors (RECIST) criteria for solid tumors has also under-
gone revisions with impacts on the definition of mRCC and 
thus patient eligibilities for clinical trials (6). Compared 
with the RECIST 1.0 (2000), reporting of metastatic disease 
in RECIST 1.1 (2009) changed in several ways: the num-
ber of target lesions decreased from 5 to 2 per organ/10 to 
5 total, LN assessment from no clear definition to specific 
measurements, PET scan was included for detection of new 
lesions, and a bone lesion >1 cm with soft tissue component 
was updated to count as a measurable disease. Additionally, 
routine bone imaging is not considered a standard practice 
in the absence of symptoms or associated laboratory abnor-
malities (7). However, the presence of osseous involvement 
may go undetected in routine body CT. 
Several landscape changes have also occurred in the 
treatment of mRCC. Before 2005, cytokines such as inter-
feron and interleukin-2 were considered standard treat-
ment options. Vascular endothelial growth factor inhibitors 
(VEGFs) and tyrosine kinase inhibitors (TKIs) have since 
gained rapid Food and Drug Administration approval and 
replaced cytokines as the standard of care for advanced and 
mRCC (8–11). Most recently, immune checkpoint inhibitors 
(ICIs) with or without TKIs have ushered in the new era of 
therapeutic possibilities (12–18).
We hypothesize that the trend of metastatic site distribu-
tion in mRCC patients is evolving with improved diagnostics 
and therapeutic advancement. We aimed to characterize the 
pattern of metastases in mRCC patients through a system-
atic analysis of prospective clinical trials published. A better 
understanding of the evolving metastatic patterns will guide 




A systematic literature review was performed to identify 
all publicly available, prospective clinical trials in mRCC 
from January 1990 to August 2018. Specifically, an inde-
pendent review of citations from the PubMed database was 
conducted. The search included the keywords “renal cell 
carcinoma,” “kidney cancer,” and/or “metastatic renal cell 
carcinoma” and was limited to phase I–III clinical trials. In 
addition, Google Scholar citation was searched and manually 
reviewed to ensure no additional clinical trials could be iden-
tified. The computer search was supplemented with a man-
ual review of the retrieved articles to establish accuracy. To 
confirm all eligible clinical trials were included, the website, 
www.ClinicalTrials.gov, was also searched manually. Dupli-
cates were disregarded, and in the event of multiple publica-
tions within the same clinical trial, the most recent, complete, 
and updated version was included in this meta-analysis. 
Patient selection
All patients in the studies that fit the criteria of phase I–III 
clinical trial published between January 1990 to August 2018, 
only recruited mRCC patients and had clear documenta-
tion of metastatic distribution were included in the analyses. 
Only distant metastasis (M1) was included in this analysis, 
and Stage IV was defined based on the American Joint Com-
mission on Cancer criteria. Studies were excluded if  patients 
with other cancers were reported, did not document metasta-
ses in the baseline characteristics, were retrospective studies, 
reviews, meta-analysis, and/or non-English publications.
The patients fitting the inclusion criteria were analyzed 
and grouped into Cytokine Era (1990–2004), VEGF-TKI 
Era (2005–2016), and ICI-TKI Era (2017–2018) based on 
the standard of care treatments offered in the respective 
time frames. Patients’ baseline characteristics were classified 
into first-line only (FLO), second-line and beyond (SLB), or 
mixed (MIX, if  the line of therapy was unclear at the time of 
metastatic sites documentation) settings.
Statistical analysis
The primary outcomes of this study were percentages of 
metastases to lung, liver, bone, and LNs. The proportions of 
metastases were calculated using the numbers of metastases 
according to lines of systemic treatments – FLO and SLB, 
respectively, for each included study. Overall percentages 
were calculated using Equation (1).
 
 Sums of the numbers of metastases




When a study had the MIX setting and did not report FLO 
and SLB separately, the numbers of metastases were esti-
mated using Equation (2).
  Number of metastases = Total number of  
  metastases of that study × percentages of FLO  
and SLB to the total sample size 
(2)
Evolving Patterns of Metastasis in mRCC
 Journal of Kidney Cancer and VHL 2021; 8(4): 13–19  15
The percentages of metastasis were calculated for each era and 
compared using Chi-square tests. A “clean” analysis was per-
formed with the exclusion of the patients in the MIX setting. 
Results
Search results
The literature search yielded 348 potential publications on 
mRCC. Excluding review articles, duplicate studies, non-En-
glish publications, editorials, meta-analyses, and observa-
tional studies, a total of 233 full-text studies were further 
reviewed. Excluding studies where metastatic site documen-
tations were unclear/unavailable, 127 studies encompassing 
16,899 mRCC patients were included in the final meta-anal-
ysis (Figure 1). Characteristics of these studies are listed in 
Table 1. Lung, liver, bone, and LN metastases were identified 
and grouped into the three predefined therapeutic timeframes.
Distribution of metastatic sites by a line of therapy 
within each treatment era 
Detailed analyses of each era are subdivided into FLO versus 
SLB and outlined in Table 2. In the Cytokine Era, more bone 
ClinicalTrials.gov Search (n = 70)
(Metastatic Renal Cell Carcinoma,
Interventional Studies, Phase 1–3, Completed
Studies, with Results)
PubMed Search (n = 312)
(Metastatic Renal Cell Carcinoma in Humans
between 1990 to present, Clinical Trial 
Phase 1–3 with Full Text available)
Full-text articles excluded
(n = 106)
Not RCC exclusive: 17
No metastatic data reported: 72
Metastatic site exclusive: 17
Studies excluded (n = 106)
No access ot not in English: 75
Not clinical trials or not original study: 40
Studies after duplicates removed
(n = 348)
Studies screened for title and abstracts
(n = 348)
Full-text studies assessed for eligibility
(n = 233)
Studies included in the final
meta-analysis (n = 127)
Figure 1: Study selection flow chart.
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(23% vs. 24% vs. 28%; P = 0.0002), and LNs (39% vs. 46% 
vs. 44%; P = 0.0002) with time. Liver disease detection was 
relative stable (22% vs. 25% vs. 23%; P = 0.0578) through 
the years. Higher detection of bone disease (15% vs. 25% vs. 
29%; P < 0.0001) and LNs (40% vs. 50% vs. 57%; P = 0.0051) 
with time was observed in the SLB setting. The distributions 
of metastases were relative stable in the lung (65% vs. 71% 
vs. 69%; P = 0.2135) and liver (22% vs. 25% vs. 23%; P = 
0.3340).
Discussion
This study represents the largest analysis of metastatic sites 
for patients with mRCC to date, examining the patterns of 
metastasis in 16,899 patients derived from 127 prospective, 
mRCC clinical trials between 1990 and 2018. Specifically, 
the overall burden of metastatic disease has increased over 
time, especially when evaluated concerning the three distinct 
metastasis was identified in the FLO compared with the SLB 
setting (23% vs. 15%; P = 0.0014). There were similar rates of 
LN (39% vs. 40%; P = 0.7773) and visceral involvements (lung: 
58% vs. 65%; P = 0.0501 and liver: 18% vs. 22%; P =0.0863) 
between the two settings. In the VEGF-TKI Era, liver and LN 
involvements were significantly higher in the SLB setting than 
the FLO setting (liver: 25% vs. 20%; P < 0.0001 and LN: 50% 
vs. 46%; P = 0.0003). Bone and lung were stable with 25% and 
70%, respectively. In the ICI-TKI Era, more LN involvement 
was identified in the SLB setting (44% vs. 57%; P = 0.0020). 
Rates of metastatic diseases in the lung (69% vs. 69%), liver 
(18% vs. 23%), and bone (28% vs. 29%) were similar. 
Distribution of metastatic sites by a line of therapy 
over the treatment eras
In the FLO setting, there were a significant increase of dis-
ease in the lung (58% vs. 70% vs. 69%; P < 0.0001), bone 




VEGF-TKI Era  
(2005–2016) 
N (%)





FLO 11 (39%) 36 (41%) 7 (58%) 54 (43%)
SLB 4 (14%) 30 (34%) 4 (33%) 38 (30%)
Mixed 13 (46%) 21 (24%) 1 (8%) 35 (28%)
Three reported metastatic 
numbers separately for 
FLO and SLB.
Three reported metastatic 
numbers separately for 
FLO and SLB.
None reported metastatic 
numbers separately for 
FLO and SLB.
Total 28 87 12 127 (100%)
VEGF-TKI, vascular endothelial growth factor/tyrosine kinase inhibitor; ICI-TKI, immune checkpoint inhibitor/tyrosine kinase inhibitor;  
N, number of patients; FLO, first-line only; SLB: second line and beyond.
Table 2: Percentage of metastasis by treatment era for all included studies (N=127).






P valueb P valuec
FLO SLB P valuea FLO SLB P valuea FLO SLB P valuea
Lung 58 % 65 % 0.0501 70 % 71 % 0.3037 69 % 69 % 0.9551 <.0001 0.2120
Liver 18 % 22 % 0.0863 20 % 25 % <.0001 18 % 23 % 0.1480 0.0578 0.3340
Bone 23 % 15 % 0.0014 24 % 25 % 0.0777 28 % 29 % 0.7244 0.0002 <.0001
LN 39 % 40 % 0.7773 46 % 50 % 0.0003 44 % 57 % 0.0020 <0.0001 0.0051
VEGF-TKI, vascular endothelial growth factor/tyrosine kinase inhibitor; ICI-TKI, immune checkpoint inhibitor/tyrosine kinase inhibitor;  
N, number of patients; FLO, first-line only; SLB: second line and beyond; LN, lymph node.
a P value based on Chi-square tests comparing % metastasis between FLO and SLB within each era.
b P value based on Chi-square tests comparing % metastasis in FLO among the three eras. 
c P value based on Chi-square tests comparing % metastasis in SLB among the three eras.
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clustered in the VEGF-TKI Era, and data from several large 
clinical trials in the ICI-TKI Era were unavailable during the 
data analysis. There is also no clear-cut “year” for classifica-
tion as the ICI-TKI era. But 2017 was selected as the cutoff  
as nivolumab, ipilimumab, pembrolizumab, and others were 
approved. Because of the overlaps between the VEGF-TKI 
and ICI-TKI Eras adoption in clinical practice, the dif-
ference before and after 2017 may not reflect the effects of 
therapeutic advancement. Sixth, most of the studies included 
were in patients with clear cell carcinoma. Some of the 
other subtypes and/or mixed histology were also included. 
The histologic and biologic behavior of nonclear cell carci-
noma may be different from those of clear cell carcinoma, 
and studies to characterize metastatic site distribution of the 
former should be considered. Lastly, our study only exam-
ined metastasis to the lung, liver, bone, and LNs in mRCC. 
The lack of consistent metastasis reporting in other visceral 
sites such as the brain (ineligible in most studies) and adrenal 
glands (inconsistent reporting) was not possible because of 
the limited data availability.
Conclusions
This study showed that the metastatic burden of disease 
in patients with mRCC has increased over the past three 
decades, with rising rates of lung, LN, and bone metastases. 
Given the unexpected high and rising rate of bone metastasis 
in this patient population, the use of clinically appropriate 
bone imaging should be considered as a diagnostic standard.
Acknowledgments
The authors thank the staff  and faculty of the Division of 
Hematology and Medical Oncology of the Tisch Cancer 
Institute at Mount Sinai, New York, NY, USA.
Author Contributions
All authors contributed to the study design; manuscript 
preparation; and data collection, analysis, and interpreta-
tion. All authors approved the final copy of the manuscript.
Conflict of Interests 
All conflicts of interest, including specific financial interests 
and relationships and affiliations relevant or not relevant to 
the subject matter or materials discussed in the manuscript 
(e.g., employment/affiliation, grants or funding, consultancies, 
honoraria, stock ownership or options, expert testimony, roy-
alties, or patents filed, received, or pending) are the following:
Lin J, Zhang Y, Hou W, Tsao CK, and Qian Q: No conflict 
of interests.
treatment eras: Cytokine, VEGF-TKI, and ICI-TKI is con-
sistent with the initial hypothesis. First, changes in clinical 
trial reporting and advances in diagnostic imaging have con-
tributed to the better definition and capturing of metastatic 
disease in this study population. Furthermore, as survival 
improves with better therapies, it is not surprising to see 
increasing overall disease burden observed in our study (19). 
Importantly, our study showed that the incidence of osse-
ous metastasis between 2017 and 2018 is 28% in FLO and 
29% in SLB, with increasing rates of bone metastasis across 
the treatment eras: FLO (23% vs. 24% vs. 28%; P = 0.0002) 
and SLB (15% vs. 25% vs. 29%; P < 0.0001). The presence 
and number of bone metastases have been associated with 
worse outcomes in patients with mRCC (20–23). Skeletal- 
related events (SREs) from osseous lesions can cause dev-
astating complications such as bone fractures, spinal cord 
compressions, decreased quality of life, and significantly 
worsened outcomes. The National Comprehensive Cancer 
Network guidelines only recommend bone scans in patients 
with symptoms and/or an elevated alkaline phosphatase 
level, as prior studies did not support its routine use in RCC 
(7, 24, 25). Furthermore, osteolytic bone lesions in advanced 
RCC tend to evade the detection on a bone scan 26. Although 
CT scan of the chest, abdomen, and pelvis can potentially 
detect bone metastases, limited imaging field and heterogene-
ity in radiologic interpretations makes capturing such lesions 
more difficult. Higher expected percentage and increasing 
incidence of bone metastases in mRCC and their subpar 
detection by CT and bone scans, it is reasonable to consider 
routine whole-body skeletal survey in patients with mRCC, 
with fluorodeoxyglucose-PET or whole-body MRI-PET as 
other alternatives (26, 27). Timely detection can lead to early 
intervention, such as the targeted radiotherapy or the incor-
poration of bone targeting agents known to decrease SREs 
(28, 29).
Our study has several limitations because of its design and 
methodology. First, this study only focused on a clinical trial 
of patients with mRCC, and its applicability to patients in 
the real world may be limited. Second, the evolving RECIST 
definitions from 2000 and 2009 may have influenced the 
observed patterns. Third, the use of cross-sectional imag-
ing routinely and the imaging quality have changed over 
the decades involved, which could contribute to the meta-
static differences. The lack of consistent reporting on what 
radiographic modalities were used to assess patients before 
the study inclusion prevents us from elucidating specific 
trends in the frequency and modality of metastatic evalua-
tion. Fourth, the settings (FLO vs. SLB) for the metastatic 
distribution were not clear for the selective studies involving 
the MIX setting. A “clean” analysis was performed wherein 
the MIX reports were excluded to ensure consistency. The 
“clean” analysis (data not shown) outcomes were not dif-
ferent from those reported here. Fifth, most samples were 
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